


Listing of Claims

1. (Previously presented) A compound of formula (I)



or a pharmaceutically acceptable salt, solvate or derivative thereof, wherein:

R⁰ is absent or C₁-C₆ alkylene;

R¹ is phenyl substituted by -SO_yR⁵, (C₁-C₆ alkylene)-SO_yR⁵, -SO_yCF₃, -(C₁-C₆ alkylene)-SO_yCF₃, -CO₂R⁵, -(C₀-C₆ alkylene)-CO₂R⁵, OCF₃, a five or six-membered aromatic heterocyclic group containing (i) from 1 to 4 nitrogen heteroatom(s) or (ii) 1 or 2 nitrogen heteroatom(s) and 1 oxygen or 1 sulphur heteroatom (said heterocyclic group being optionally substituted by halo, oxo, -CN, -COR⁵, -CO₂R⁵, -CONR⁵R⁵, -SO_yR⁵, -SO_yCF₃, -SO₂NR⁵R⁵, -NR⁵SO₂R⁵, -OR⁵, -OCF₃, -NR⁵R⁵, -(C₁-C₆ alkylene)-NR⁵R⁵, C₁-C₆ alkyl, fluoro(C₁-C₆)alkyl or C₃-C₇ cycloalkyl); or, when R⁰ is C₁-C₆ alkylene, R¹ may also be a five or six-membered aromatic heterocyclic group containing (i) from 1 to 4 nitrogen heteroatom(s) or (ii) 1 or 2 nitrogen heteroatom(s) and 1 oxygen or 1 sulphur heteroatom or (iii) 1 or 2 oxygen or sulphur heteroatom(s), said heterocyclic group being optionally substituted by halo, oxo, -CN, -COR⁵, -CONR⁵R⁵, -SO₂NR⁵R⁵, -NR⁵SO₂R⁵, -OR⁵, -OR¹¹, -NR⁵R⁵, -(C₁-C₆ alkylene)-NR⁵R⁵, R⁷ or R¹¹; said phenyl being optionally additionally substituted by halo, -CN, -COR⁵, -CONR⁵R⁵, -SO₂NR⁵R⁵, -NR⁵SO₂R⁵, -OR⁵, -NR⁵R⁵, -(C₁-C₆ alkylene)-NR⁵R⁵, C₁-C₆ alkyl, halo(C₁-C₆)alkyl or C₃-C₇ cycloalkyl;

R² is H, C₁-C₆ alkyl, C₃-C₆ alkenyl, C₃-C₆ alkynyl, C₃-C₇ cycloalkyl, C₃-C₇ cycloalkenyl, phenyl, benzyl, R⁸ or R⁹, said C₁-C₆ alkyl, C₃-C₇ cycloalkyl, phenyl and benzyl being optionally substituted by halo, -OR⁵, -OR¹⁰, -CN, -CO₂R⁷, -OCONR⁵R⁵, -CONR⁵R⁵, -C(=NR⁵)NR⁵OR⁵, -CONR⁵NR⁵R⁵, -NR⁶R⁶, -NR⁵R¹⁰, -NR⁵COR⁵, -NR⁵COR⁸, -NR⁵COR¹⁰, -NR⁵CO₂R⁵, -NR⁵CONR⁵R⁵, -SO₂NR⁵R⁵, -NR⁵SO₂R⁵, -NR⁵SO₂NR⁵R⁵, R⁸ or R⁹;

R^3 is H, C_1 - C_6 alkyl, C_3 - C_7 cycloalkyl, phenyl, benzyl, halo, -CN, -OR⁷, -CO₂R⁵, -CONR⁵R⁵, R⁸ or R⁹, said C_1 - C_6 alkyl, C_3 - C_7 cycloalkyl, phenyl and benzyl being optionally substituted by halo, -CN, -OR⁵, -CO₂R⁵, -CONR⁵R⁵, -OCONR⁵R⁵, -NR⁵CO₂R⁵, -NR⁶R⁶, -NR⁵COR⁵, -SO₂NR⁵R⁵, -NR⁵CONR⁵R⁵, -NR⁵SO₂R⁵, R⁸ or R⁹;

R^4 is phenyl, naphthyl or pyridyl, each being optionally substituted by R⁸, halo, -CN, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_3 - C_7 cycloalkyl, C_1 - C_6 alkoxy, -CONR⁵R⁵, OR¹¹, SO_xR⁶, O-(C_1 - C_6 alkylene)-CONR⁵R⁵, O-(C_1 - C_6 alkylene)-NR⁵R⁵, or O-(C_1 - C_6 alkylene)-OR⁶;

each R⁵ is independently either H, C_1 - C_6 alkyl or C_3 - C_7 cycloalkyl or, when two R⁵ groups are attached to the same nitrogen atom, those two groups taken together with the nitrogen atom to which they are attached represent azetidiny, pyrrolidiny, piperidiny, homopiperidiny, piperaziny, homopiperaziny or morpholiny, said azetidiny, pyrrolidiny, piperidiny, homopiperidiny, piperaziny, homopiperaziny and morpholiny being optionally substituted by C_1 - C_6 alkyl or C_3 - C_7 cycloalkyl;

each R⁶ is independently either H, C_1 - C_6 alkyl or C_3 - C_7 cycloalkyl;

R⁷ is C_1 - C_6 alkyl or C_3 - C_7 cycloalkyl;

R⁸ is a five or six-membered, aromatic heterocyclic group containing (i) from 1 to 4 nitrogen heteroatom(s) or (ii) 1 or 2 nitrogen heteroatom(s) and 1 oxygen or 1 sulphur heteroatom or (iii) 1 or 2 oxygen or sulphur heteroatom(s), said heterocyclic group being optionally substituted by halo, oxo, -CN, -COR⁵, -CONR⁵R⁵, -SO₂NR⁵R⁵, -NR⁵SO₂R⁵, -OR⁵, -NR⁵R⁵, -(C_1 - C_6 alkylene)-NR⁵R⁵, C_1 - C_6 alkyl, fluoro(C_1 - C_6)alkyl or C_3 - C_7 cycloalkyl;

R⁹ is a four to seven-membered, saturated or partially unsaturated heterocyclic group containing (i) 1 or 2 nitrogen heteroatom(s) or (ii) 1 nitrogen heteroatom and 1 oxygen or 1 sulphur heteroatom or (iii) 1 oxygen or sulphur heteroatom, said heterocyclic group being optionally substituted by oxo, C_1 - C_6 alkyl, C_3 - C_7 cycloalkyl, -SO₂R⁵, -CONR⁵R⁵, -COOR⁵, -CO-(C_1 - C_6 alkylene)-OR⁵ or -COR⁵ and optionally substituted on a carbon atom which is not adjacent to a heteroatom by halo, -OR⁵, -NR⁵R⁵, -NR⁵COR⁵, -NR⁵COOR⁵, -NR⁵CONR⁵R⁵, -NR⁵SO₂R⁵ or -CN;

R¹⁰ is C_1 - C_6 alkyl substituted by R⁸, R⁹, -OR⁵, -CONR⁵R⁵, -NR⁵COR⁵ or -NR⁵R⁵;

R¹¹ is phenyl optionally substituted by halo, -CN, -COR⁵, -CONR⁵R⁵, -SO₂NR⁵R⁵, -NR⁵SO₂R⁵, -OR⁵, -NR⁵R⁵, -(C₁-C₆ alkylene)-NR⁵R⁵, C₁-C₆ alkyl, halo(C₁-C₆)alkyl or C₃-C₇ cycloalkyl; and

x and y are independently 0, 1 or 2.

2. (Currently amended) A pharmaceutical composition ~~including a compound of formula (I) comprising a compound according to claim 1 or a pharmaceutically acceptable salt, solvate or derivative thereof~~ together with one or more pharmaceutically acceptable excipients, diluents or carriers.

3. (Currently amended) A pharmaceutical composition according to claim 2 ~~including~~ comprising one or more additional therapeutic agents.

4. (Canceled) ~~A compound of formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof, or a pharmaceutical composition according to claim 2, for use as a medicament.~~

5. (Canceled) ~~A compound of formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof, or a pharmaceutical composition according to claim 3, for use as a medicament.~~

6. (Canceled) ~~A compound of formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof, or a pharmaceutical composition according to claim 2, for use as a reverse transcriptase inhibitor or modulator.~~

7. (Canceled) ~~A compound of formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof, or a pharmaceutical composition according to claim 3, for use as a reverse transcriptase inhibitor or modulator.~~

8. (Canceled) ~~A compound of formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof, or a pharmaceutical composition according to claim 2, for use in the treatment of an HIV or genetically related retroviral infection, or a resulting acquired immune deficiency syndrome (AIDS).~~

9. (Canceled) ~~A compound of formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof, or a pharmaceutical composition according to claim 3, for use in the~~

~~treatment of an HIV or genetically related retroviral infection, or a resulting acquired immune deficiency syndrome (AIDS).~~

10. (Withdrawn) Use of a compound of formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof, or a pharmaceutical composition according to claim 2, for the manufacture of a medicament having reverse transcriptase inhibitory or modulating activity.

11. (Withdrawn) Use of a compound of formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof, or a pharmaceutical composition according to claim 3, for the manufacture of a medicament having reverse transcriptase inhibitory or modulating activity.

12. (Withdrawn) Use of a compound of formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof, or a pharmaceutical composition according to claim 2, for the manufacture of a medicament for the treatment of an HIV or genetically-related retroviral infection, or a resulting acquired immune deficiency syndrome (AIDS).


13. (Withdrawn) Use of a compound of formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof, or a pharmaceutical composition according to claim 3, for the manufacture of a medicament for the treatment of an HIV or genetically-related retroviral infection, or a resulting acquired immune deficiency syndrome (AIDS).

14. (Withdrawn) A method of treating an HIV or a genetically-related retroviral infection, or a resulting acquired immune deficiency syndrome (AIDS), comprising administering an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof, or a pharmaceutical composition according to claim 2.

15. (Withdrawn) A method of treating an HIV or a genetically-related retroviral infection, or a resulting acquired immune deficiency syndrome (AIDS), comprising administering an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof, or a pharmaceutical composition according to claim 3.


16. (Withdrawn) A process for preparing the compound of formula (I) or a salt, solvate or pharmaceutically acceptable derivative thereof, which comprises:

- (A) reaction of a compound of formula (V)




with an alcohol of formula (IV), R^1 -OH (IV), under conventional conditions;

- (B) reaction of an alcohol of formula (III)



with a compound of formula (II), $Lg-R^1$ (II), under conventional conditions;

- (C) reaction of a compound of formula (III) with an alcohol of formula (IV) under dehydrating conditions;
- (D) for the preparation of a compound of formula (I) in which R^3 is halo, halogenating a compound of formula (X)



under conventional conditions;

(E) interconversion of a compound of formula (I) into another compound of formula (I); or

(F) deprotecting a protected derivative of compound of formula (I); and

optionally converting a compound of formula (I) prepared by any one of processes (A) to (F) into pharmaceutically acceptable salt, solvate or derivative thereof.

17. (Withdrawn) A compound of formulae (III), (V) or (X).